Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes
Authors:
- 12 January 2016
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 25 (3) , 287-296
Abstract
Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes. . ???aop.label???. doi: 10.1517/13543784.2016.1142531Keywords
This publication has 45 references indexed in Scilit:
- Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer TherapiesInternational Journal of Molecular Sciences, 2014
- Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and futureThe Lancet, 2014
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemiasInternational Journal of Clinical Oncology, 2007
- Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulationOncogene, 2005
- Glucose transport regulation by p210 Bcr–Abl in a chronic myeloid leukaemia modelBritish Journal of Haematology, 2001
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial InfarctionNew England Journal of Medicine, 1998
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993